BioCatalystWatch
ADCTWorkspace / ADCT / OverviewCompany library
Price
Market cap
Next catalystDec 12, 2026ZYNLONTA consolidation — COLUMN · Phase 2 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

ZYNLONTA + rituximab — LOTIS-5

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

CD19

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

ZYNLONTA consolidation — COLUMN

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

CD19

Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

CD19

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

ZYNLONTA + rituximab — LOTIS-5

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

CD19

Upcoming / outlook

  • Timing and evidence

ZYNLONTA consolidation — COLUMN

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

ADCT-241

PSMA

Partner / License out

CD19

CD19

PreINDP1P2P3FilingApproved

Approved / commercial

CD19

Approved

PreINDP1P2P3FilingApproved

History / paused

CD25

PreINDP1P2P3FilingApproved

CD19

PreINDP1P2P3FilingApproved

PSMA

PreINDP1P2P3FilingApproved

AXL

PreINDP1P2P3FilingApproved

AXL

PreINDP1P2P3FilingApproved

AXL

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ADCT PR & News

PR & News

ADCT SEC archive